Loading...
The FDA's approval on August 18, 2015, of flibanserin (Addyi) as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women is the first approval of a medication for this condition. Initially investigated for depression, flibanserin modulates serotonin's action and thereby, on balance, increases sexual desire.
In one trial, the proportion of participants who reported a meaningful benefit from study medications was 45% with flibanserin and 35% with placebo. In another trial, these proportions were 39% and 27%, respectively. These results suggest that ten women would need to be treated to benefit one. Overall, compared with placebo, flibanserin increased the average number of satisfying sexual events by at most one per mon…